CollPlant Biotechnologies (CLGN) Q1 2026 earnings summary

Executive summary

• Initiated discussions with leading strategic players for potential collaborations in medical aesthetics, focusing on joint development and commercialization of next-generation dermal filler candidates using rhCollagen technology.

• Advanced development of a photocurable dermal filler platform, now in final preclinical stage, targeting age-related volume loss and facial changes from weight reduction.

• Launched BioFlex, a ready-to-print rhCollagen-based kit for high-resolution DLP bioprinting, supporting tissue modeling and regenerative medicine research.

• Evaluating strategic alternatives, including acquisitions and business combinations, to maximize shareholder value.

Financial highlights

• GAAP revenues for Q1 2026 were $73,000, down from $2.1 million in Q1 2025, mainly due to a non-recurring $2.0 million milestone payment in the prior year.

• GAAP gross loss was $243,000 in Q1 2026 versus a gross profit of $1.9 million in Q1 2025.

• GAAP operating expenses decreased to $2.9 million from $3.5 million year-over-year, reflecting cost reduction measures.

• GAAP net loss was $3.1 million ($0.23 per share) compared to $1.5 million ($0.13 per share) in Q1 2025; non-GAAP net loss was $2.9 million ($0.21 per share) versus $1.1 million ($0.10 per share) year-over-year.

• Cash and cash equivalents as of March 31, 2026, were $4.3 million.

Outlook and guidance

• Targeting initiation of clinical studies for regenerative dermal and soft tissue fillers within two years.

• Actively engaging with potential strategic partners to support next development and commercialization phases.